U.S. Markets open in 2 hrs 39 mins

Analysts Are Mostly Positive on Neurocrine Biosciences

Daniel Collins
Analysts Are Mostly Positive on Neurocrine Biosciences

Neurocrine Biosciences (NBIX) develops and commercializes therapies for neurology and endocrine disorders. Neurocrine Biosciences’ Ingrezza became the first FDA-approved drug to be approved for the treatment of individuals with tardive dyskinesia. Neurocrine Biosciences’ Ingrezza competes with Teva Pharmaceutical’s (TEVA) Austedo in the tardive dyskinesia drugs market.